Molecular Profile Detail

Profile Name MET over exp
Gene Variant Detail

MET over exp (no effect)

Relevant Treatment Approaches HGF Antibody MET Antibody MET Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET over exp hepatocellular carcinoma sensitive SCC244 Preclinical - Pdx Actionable In a preclinical study, hepatocellular carcinoma patient-derived xenograft (PDX) models overexpressing MET were sensitive to SCC244, demonstrating a complete response in one and partial response in eleven (PMID: 29237805). 29237805
MET over exp triple-receptor negative breast cancer unknown MET Inhibitor BKM120 + Crizotinib Preclinical - Cell line xenograft Actionable In a preclinical study, triple-receptor negative breast cancer xenograft models overexpressing MET demonstrated stable disease when treated with the combination therapy, BKM120 and Xalkori (crizotinib) (PMID: 29203461). 29203461
MET over exp non-small cell lung carcinoma sensitive SCC244 Preclinical - Pdx Actionable In a preclinical study, non-small cell lung carcinoma patient-derived xenograft (PDX) models harboring MET overexpression were sensitive to SCC244, demonstrating inhibition of tumor growth and nine partial responses (PMID: 29237805). 29237805
MET over exp melanoma sensitive XL147 Preclinical Actionable In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314). 25637314
MET over exp stomach cancer sensitive MET Antibody SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in patient-derived xenograft (PDX) models of gastric cancer with high Met expression (PMID: 28679766). 28679766
MET over exp stomach cancer sensitive MET Inhibitor Crizotinib Preclinical - Cell culture Actionable In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108). 26432108
MET over exp hepatocellular carcinoma sensitive MET Inhibitor Tepotinib Preclinical - Pdx Actionable In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830). 25256830
MET over exp hepatocellular carcinoma no benefit MET Inhibitor Tivantinib Phase III Actionable In a Phase III trial, second-line treatment with Tivantinib (ARQ197) did not result in improved overall survival over placebo in hepatocellular carcinoma patients with high MET expression (PMID: 29625879; NCT01755767). 29625879
MET over exp lung papillary adenocarcinoma sensitive MET Antibody Telisotuzumab vedotin Preclinical - Cell culture Actionable In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171). 27573171
MET over exp colorectal cancer sensitive MET Inhibitor JNJ 38877605 + Panitumumab Preclinical - Cell culture Actionable In a preclinical study, the addition of JNJ-38877605 to Vectibix (panitumumab) treatment overcame Vectibix (panitumumab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478). 23729478
MET over exp triple-receptor negative breast cancer decreased response Rucaparib Preclinical - Cell culture Actionable In a preclinical study, triple-receptor negative breast cancer cell lines overexpressing Met demonstrated decreased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812). 26779812
MET over exp lung small cell carcinoma sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427). 25122427
MET over exp cholangiocarcinoma predicted - sensitive MET Inhibitor Cabozantinib Phase II Actionable In a Phase II trial, a cholangiocarcinoma patient with high Met expression in tumor stayed on Cometriq (cabozantinib) treatment for 278 days (PMID: 28192597). 28192597
MET over exp triple-receptor negative breast cancer sensitive MET Inhibitor Foretinib + Veliparib Preclinical - Cell line xenograft Actionable In a preclinical study, Foretinib (GSK1363089) and Veliparib (ABT-888) worked synergistically to inhibit growth of Met-over expressing triple-receptor negative breast cancer cells in culture, and reduced tumor growth in xenograft models (PMID: 26779812). 26779812
MET over exp lung cancer sensitive MET Antibody SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in both cell line xenograft and patient-derived xenograft (PDX) models of lung cancer with high Met expression (PMID: 28679766). 28679766
MET over exp stomach cancer sensitive MET Inhibitor KRC-00509 Preclinical Actionable In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760). 26801760
MET over exp lung squamous cell carcinoma sensitive MET Inhibitor EMD 1214063 Preclinical - Cell culture Actionable In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing lung squamous cell carcinoma cells in culture (PMID: 26358474). 26358474
MET over exp triple-receptor negative breast cancer sensitive MET Inhibitor Foretinib + Rucaparib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) and Rubraca (rucaparib) combination treatment resulted in enhanced growth inhibition in Met-over expressing triple-receptor negative breast cancer cells in culture (PMID: 26779812). 26779812
MET over exp stomach cancer sensitive MET Inhibitor Merestinib Preclinical - Cell line xenograft Actionable In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061). 23275061
MET over exp lung cancer sensitive MET Inhibitor Crizotinib + Rucaparib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812). 26779812
MET over exp glioblastoma multiforme predicted - sensitive MET Inhibitor Altiratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451). 26965451
MET over exp colorectal cancer sensitive MET Inhibitor Cetuximab + JNJ 38877605 Preclinical - Cell culture Actionable In a preclinical study, the addition of JNJ-38877605 to Erbitux (cetuximab) treatment overcame Erbitux (cetuximab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478). 23729478
MET over exp lung adenocarcinoma sensitive MET Inhibitor Merestinib Preclinical - Cell line xenograft Actionable In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of lung adenocarcinoma with Met over expression (PMID: 23275061). 23275061
MET over exp triple-receptor negative breast cancer sensitive MET Inhibitor Crizotinib + Rucaparib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of Met-over expressing human triple-receptor negative breast cancer cell lines in culture, and reduced tumor growth in xenograft models (PMID: 26779812). 26779812
MET over exp lung adenocarcinoma predicted - sensitive MET Antibody Telisotuzumab vedotin Preclinical - Pdx Actionable In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171). 27573171
MET over exp stomach cancer sensitive MET Inhibitor KRC-00715 Preclinical Actionable In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760). 26801760
MET over exp colorectal cancer resistant Panitumumab Preclinical - Cell culture Actionable In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478). 23729478
MET over exp non-small cell lung carcinoma sensitive MET Antibody Erlotinib + Telisotuzumab vedotin Phase I Actionable In a Phase I trial, the combination of Telisotuzumab vedotin (ABBV-399) and Tarceva (erlotinib) resulted in a partial response in 31% (4/13) of non-small cell lung carcinoma patients and disease control at 12 weeks in 61.5% (8/13) of patients (J Clin Oncol 35, 2017 (suppl; abstr 2509)). detail...
MET over exp non-small cell lung carcinoma sensitive MET Antibody Telisotuzumab vedotin Phase I Actionable In a Phase I trial, Telisotuzumab vedotin (ABBV-399) was well-tolerated and resulted in a disease control rate of 56% (9/16) in patients with MET-overexpressing non-small cell lung cancer, with partial response in 19% (3/16) and stable disease in 38% (6/16), and resulted in reduction in target lesions in 44% (7/16) of patients (PMID: 30285518; NCT02099058). detail... 30285518
MET over exp non-small cell lung carcinoma sensitive MET Antibody Telisotuzumab vedotin Preclinical - Cell culture Actionable In a preclinical study, Telisotuzumab vedotin (ABBV-399) inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171). 27573171
MET over exp stomach carcinoma sensitive MET Inhibitor EMD 1214063 Preclinical - Cell culture Actionable In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474). 26358474
MET over exp colorectal cancer resistant Cetuximab Preclinical - Cell culture Actionable In a preclinical study, over expression of MET conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture (PMID: 23729478). 23729478
MET over exp breast cancer sensitive MET Inhibitor Crizotinib + Rucaparib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human breast cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812). 26779812
Clinical Trial Phase Therapies Title Recruitment Status
NCT03040973 FDA approved Capmatinib Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study Recruiting
NCT03213626 Phase II Cabozantinib + Erlotinib Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma Recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT03175224 Phase I CBT-101 CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation Recruiting
NCT03147976 Phase II AMG 337 QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors Recruiting